Cargando…
Transdermal selegiline for the treatment of major depressive disorder
Non-selective inhibition of monoamine oxidase (MAO) enzymes (ie, isoforms A and B) in the brain are associated with clinically significant antidepressant effects. In the US, the selegiline transdermal system (STS; EMSAM) is the first antidepressant transdermal delivery system to receive Food and Dru...
Autores principales: | Lee, Kelly C, Chen, Jack J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656289/ https://www.ncbi.nlm.nih.gov/pubmed/19300583 |
Ejemplares similares
-
Desvenlafaxine in the treatment of major depressive disorder
por: Lourenco, Maria Teresa C, et al.
Publicado: (2009) -
Duloxetine in the treatment of major depressive disorder
por: Goldstein, David J
Publicado: (2007) -
Augmentation treatment in major depressive disorder: focus on aripiprazole
por: Nelson, J Craig, et al.
Publicado: (2008) -
New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine
por: Baune, Bernhard T
Publicado: (2008) -
Rotigotine transdermal system: a short review
por: Bunten, Sabine, et al.
Publicado: (2006)